PKR Activator Modulates 2,3-DPG and ATP to Increase Hemoglobin Oxygen Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease (SCD) and beta thalassemia are inadequate, with a need for noninvasive, disease-modifying therapies that are safe and effective, as existing options are limited in efficacy and tolerability, leading to significant morbidity and reduced quality of life for patients.
Innovation Solution
The administration of Compound 1, a selective PKR activator that decreases 2,3-DPG and increases ATP in erythrocytes, administered once daily to increase hemoglobin oxygen affinity and reduce RBC sickling, thereby improving RBC health and reducing hemolysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for sickle cell disease are used, then some therapeutic effect is achieved, but safety and tolerability are compromised due to significant side effects and morbidity
Solution Approach 1:
The patent changes the biochemical parameters within red blood cells by modulating the 2,3-DPG to ATP ratio through PKR activation. This parameter change increases hemoglobin oxygen affinity and reduces sickling, achieving therapeutic efficacy without the harmful side effects of current treatments like hydroxyurea, voxelotor, and crizanlizumab
2Reliability
If existing therapeutic modalities are administered, then some clinical benefits are obtained, but the treatment paradigm remains incomplete in addressing underlying anemia and reducing vaso-occlusive crises
Solution Approach 1:
The patent employs a multi-functional mechanism where PKR activation simultaneously achieves multiple therapeutic goals: increases ATP production, decreases 2,3-DPG levels, increases hemoglobin oxygen affinity, reduces sickling, and improves RBC membrane health. This single mechanism addresses both underlying anemia and vaso-occlusive crises, providing a complete treatment paradigm
3Object-affected harmful factors
If hemoglobin oxygen affinity is increased to reduce deoxygenation, then polymer formation and sickling are decreased, but the allosteric transition and oxygen release dynamics must be maintained
Solution Approach 1:
The patent carefully modulates the 2,3-DPG to ATP ratio rather than dramatically shifting allosteric equilibrium. By activating PKR to increase ATP and decrease 2,3-DPG, the invention increases oxygen affinity enough to reduce sickling while maintaining sufficient oxygen release to tissues through controlled parameter changes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Compound 1 demonstrates durable pharmacodynamic responses, including increased hemoglobin oxygen affinity and reduced 2,3-DPG levels, leading to improved RBC membrane health and reduced vaso-occlusive crises, with a favorable safety profile and potential for disease modification.
Implementation Method 1
Compound 1 is a selective PKR activator that decreases 2,3-DPG and increases ATP in erythrocytes
Implementation Method 2
Each heme contains porphyrin and ferrous iron that reversibly binds oxygen through an iron-oxygen bond
Data Source
AI summary
The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.